AMCP

PARTNERSHIP FORUM

No. 3 — 2021

Addressing Evidence Gaps in the Expedited Review Process: Payer Perspectives

NOV. 18–19, 2021 | THE ALEXANDRIAN OLD TOWN | HYBRID

As of Nov. 15, 2021

WELCOME

Thank you for your participation in this important Partnership Forum, which will explore Payer Perspectives in Addressing Evidence Gaps in the Expedited Review Process.

AMCP has been at the forefront of health care innovation for more than 30 years, and today we continue that proud tradition by taking a leadership position around addressing and identifying solutions in faster coverage determinations and payment for new and innovative treatments.

Today, more than 50% of novel drug approvals utilize at least one of the FDA's four regulatory pathways to speed the development of medications for serious conditions. When drugs are approved via expedited pathways and the accelerated approval program, payer expectations can differ from those established to meet FDA regulations.

However, we know meeting payers' expectations is critical for patient access and commercial success. Payers want more evidence about treatment efficacy and safety to ensure value, especially for high investment medications.

This Partnership Forum has two goals: the first is to identify payer needs and current barriers for therapies approved through the expedited review programs and accelerated approval process. The second goal of this meeting is to identify potential solutions to address evidence gaps and reduce the financial uncertainty for these products.

During our invitation-only Partnership Forums, we rely on a range of perspectives, including those of payers, integrated delivery system leaders, patient advocates, academicians, providers, pharmaceutical manufacturers, and other health care stakeholders. Our efforts here collaboratively help shape the changing health care landscape.

Thank you to our generous sponsors that make this event possible: Gilead, Janssen, Pfizer, PhRMA, SeaGen, Takeda, and uniQure.

Following the forum, AMCP will produce proceedings documenting findings and recommendations in an upcoming issue of AMCP's *Journal of Managed Care + Specialty Pharmacy,* which is widely disseminated to decision makers around the country. Also, we also plan to present a webinar summarizing the findings and recommendations.

I look forward to this AMCP Partnership Forum and its resulting findings and recommendations. Thank you for your participation.

Sincerely,

Susan A. Cantrell, RPh, CAE
AMCP CEO

MODERATOR

Jeff Lee, PharmD, FCCP

Associate Dean for Academic Affairs
Lipscomb University College of Pharmacy

Dr. Lee is the associate dean for Academic Affairs at Lipscomb University College of Pharmacy in Nashville. He joined Lipscomb in 2013 after more than 20 years in the pharmaceutical industry focused on pharmacoeconomic and health outcomes research. He is active in numerous national pharmacy associations and was AMCP's Format Executive Committee Chair from 2015-2018, leading a group of national payer, industry, and academic experts on all matters related to the AMCP Format for Formulary Submissions. He led the development of fellowship training guidelines in pharmacoeconomics for the American College of Clinical Pharmacy and was elected as an ACCP Fellow in 2003.

AGENDA

THURSDAY, NOV. 18

2–2:30pm	**Welcome and Introductions**
2:30–3:15pm	**Presentation and Discussion:** History and Current Opportunities and Challenges with the FDA Expedited Review Program
3:15–3:45pm	**Presentation: AMCP Foundation Survey Results**
3:45–4pm	**Break**
4–4:45pm	**Panel:** Treatment Outcomes Valued by Stakeholders
4:45–6pm	**Breakout Session #1:** Identify Gaps Between the FDA Expedited Review Requirements and Payer Coverage Needs
6–6:30pm	**Report Out**
6:30pm	**Reception**

HOSTED BY AMCP IN PARTNERSHIP WITH

AGENDA

FRIDAY, NOV. 19

7–8am	**Breakfast**
8–8:15am	**Welcome and Day 1 Debrief**
8:15–9am	**Panel:** Bridging the Gaps by Building an Evidence Ecosystem
9–10:15am	**Breakout Session #2:** Identify Potential Solutions to Address Evidence Gaps
10:15–10:30am	**Break**
10:30–11am	**Report Out**
11am–12pm	**Panel:** Communication Opportunities and Policy Solutions to Reduce Financial Uncertainty
12–12:45pm	**Networking Lunch**
12:45–2pm	**Breakout Session #3:** Identify Policy Solutions to Reduce Financial Uncertainty and Potentially Shorten the Time Between FDA Approval and Coverage Decisions
2–2:30pm	**Report Out**
2:30–2:45pm	**Forum Summary and Conclusions**



PARTICIPANTS

Thomas Barker

Partner, Co-Chair, Healthcare Practice
Foley Hoag

Thomas Barker has been a partner at Foley Hoag since March of 2009. He focuses his practice on complex federal and state health care legal and regulatory matters with a special expertise in Medicare and Medicaid law including coverage, reimbursement, and regulatory oversight. In May of 2019, he was appointed as a commissioner of the Medicaid and CHIP Payment and Access Commission (MACPAC), an advisory body that provides policy advice to Congress and the states on the Medicaid and CHIP programs. Previously, he was acting General Counsel of the U.S. Department of Health and Human Services (HHS) and General Counsel of the Centers for Medicare & Medicaid Services (CMS).

Diana Brixner, RPH, PhD, FAMCP

Professor
University of Utah

Dr. Diana Brixner is currently a professor in the department of pharmacotherapy and is the executive director of the Pharmacotherapy Outcomes Research Center at the University of Utah. She holds two adjunct positions in the department of population health sciences and department of pediatrics, division of clinical pharmacology. Dr. Brixner received her bachelor of science degree in 1982 from the University of Rhode Island, Pharmacy. Then in 1987 received her PhD in medicinal chemistry from the University of Utah. She is a long-standing member and past president of AMCP, and currently serves as the Board Director for the BBCIC.

Lisa Cashman, PharmD

Vice President Specialty Solutions
MedImpact Healthcare Systems

Lisa Cashman is vice president of specialty solutions at MedImpact Healthcare Systems. She is responsible for specialty drug management and trend, sales support and programs in medical specialty management, gene and CAR-T therapy financial solutions, and pharmacogenomics. Lisa has expertise in managed care pharmacy, specialty, and PBM. She serves as Chair of the Format Executive Committee at AMCP. Lisa graduated from UCSF School of Pharmacy and lives in San Diego, CA.

PARTICIPANTS

Vivien Chan, PharmD

Director, Formulary and Contracting
Costco Health Solutions

Vivien Chan, PharmD, has more than 20 years of experience in managed care pharmacy. Before joining Costco Health Solutions, she was the director of the clinical account management and quality/Stars program development teams at Regence BCBS. Prior to that, Dr. Chan spent 18 years at Group Health Cooperative in WA (now Kaiser Permanente WA). Her last position there was serving as the manager of clinical operations where she was responsible for formulary/policy management, prior authorization operations, and Medicare Stars performance. Dr. Chan completed her pharmacy residency at Group Health Cooperative. She received her doctor of pharmacy at University of Washington, and bachelor of science degree in pharmacy at University of Wisconsin-Madison.

Elizabeth Cherry, PharmD, MMHC, CSP

Program Director, Trade Relations and Market Access
Vanderbilt Specialty Pharmacy

Elizabeth Cherry, PharmD, MMHC, CSP, is the program director of trade relations at Vanderbilt Specialty Pharmacy in Nashville, TN. In this role, she collaborates with key stakeholders within the healthcare industry to create and implement solutions that capitalize on the contribution Vanderbilt Specialty Pharmacy is uniquely qualified to give to its patients and partners. Elizabeth has gained both clinical and operational experience in several pharmacy outlets including independent, hospital, and specialty pharmacy. Elizabeth received her doctorate from Lipscomb University College of Pharmacy.

Joe Couto, PharmD, MBA

Sr Director – Specialty Program Evaluation and Outcomes
CVS Health

Joe Couto, PharmD, is the senior director of specialty program evaluation and outcomes for CVS Health. Prior to CVS Health, Joe was a data science director at Cigna Healthcare. He received his doctor of pharmacy and master of business administration degrees from SUNY Buffalo and completed a research fellowship at Thomas Jefferson University. Joe is the current AMCP Joint Research Committee Chair, is on the editorial board of American Health & Drug Benefits and serves on the Specialty Board of the Pharmacist's Letter/ Prescriber's Letter.

PARTICIPANTS

Jennifer Day, PharmD

Manager, Drug Intelligence and Strategy
Kaiser Permanente

Jennifer Day, PharmD is the manager of drug intelligence and strategy for Kaiser Permanente National Pharmacy. Dr. Day's areas of expertise include drug information and analysis of clinical trial evidence, formulary management, development of evidence-based guidelines, pharmaceutical pipeline forecasting, and strategic planning for the use of biologics and emerging pharmaceuticals, including gene therapies and biosimilars.

Nancy Dreyer, PhD, MPH

Chief Scientific Officer
IQVIA

Dr. Nancy Dreyer is the chief scientific officer and senior vice president at IQVIA, and adjunct professor of epidemiology at the University of NC School of Global Public Health. Her current work is focused on COVID-19 along with other issues of regulatory and public health importance. A Fellow of both DIA and the International Society of Pharmacoepidemiology, she is widely known for her thought leadership, including her user guides for patient registries and her paper "Advancing a framework for regulatory use of real-world evidence: When real is reliable," which received DIA's 2019 Global Inspire Award for Author of the Year.

Ryan Fischer

Chief Advocacy Officer
Parent Project Muscular Dystrophy

Ryan Fischer is the chief advocacy officer for Parent Project Muscular Dystrophy (PPMD) and has been with the organization for 17 years. PPMD is the leading organization in the fight to end Duchenne muscular dystrophy. Within PPMD, Ryan oversees all programming under advocacy, care, research, and co-leads the strategic development of the largest patient-reported registry in Duchenne developed by PPMD, The Duchenne Registry.

PARTICIPANTS

Estay Greene, PharmD, MBA

VP, Pharmacy
Zing Health

Estay Greene, PharmD, MBA, is vice president of pharmacy for Zing Health. He is responsible for establishing a pharmacy department and strategy focused on providing high-quality cost-effective care for a new Medicare Advantage Plan. His areas of responsibility include formulary management, Part D Star ratings, PBM oversight, and Part B drug programs. Prior to his current position, he was vice president of pharmacy services for Blue Cross and Blue Shield of North Carolina (Blue Cross NC) and director of pharmacy benefits for the Cleveland Clinic/Cleveland Health Network.

Robert Greer

Sr. Director, Clinical Strategy and Programs
Magellan Rx Management

Robert Greer is the senior director of clinical strategy and programs at Magellan Rx Management. In this role, he is responsible for the development of specialty medication clinical criteria as well as clinical decision tree development for health plan clients. Bob is a board-certified oncology pharmacist and a graduate (BS Pharm) from the St. Louis College of Pharmacy (now University of Health Sciences and Pharmacy in St. Louis).

Dorothy Hoffman, MPP

Access Innovation Lead
Pfizer

Dorothy Hoffman serves as access innovation external engagement lead in Pfizer's Healthcare Innovation Center. The Healthcare Innovation Center is responsible for exploring new partnerships across the health care ecosystem to catalyze value-based health care centered on equitable and affordable access for patients. Hoffman has more than 17 years of experience working in the biopharmaceutical and health care industry. Most recently, she served as vice president of prescription drug policy at UnitedHealth Group. Hoffman earned a certification in design thinking and a master of public policy.

PARTICIPANTS

Saira Jan, MS, PharmD

Vice President and Chief Pharmacy Officer
Horizon Blue Cross Blue Shield of New Jersey

Dr. Saira Jan is the vice president and chief pharmacy officer of Horizon BCBSNJ and is the Professor Emerita at Rutgers State University of NJ where she oversees Horizon's pharmacy and medical integration initiatives for commercial, Medicaid, and Medicare lines of business. Dr. Jan has more than 25 years of experience in health care management, academics, and outcome-based research projects with Harvard University and other nationally acclaimed institutions. She works closely with business units, clinical quality groups and medical management teams to deliver integrated and comprehensive services for over 3.5 million lives.

Annie Kennedy

Chief of Policy, Advocacy, & Patient Engagement
EveryLife Foundation for Rare Diseases

Focused on improving health outcomes for people living with rare diseases by advancing the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy, Annie's work includes building strong partnerships with policy makers, federal agencies, and alliances. She has served within the community for nearly three decades through her previous roles with Parent Project Muscular Dystrophy (PPMD) and the Muscular Dystrophy Association (MDA). In that time she helped lead legislative efforts and engaged with ICER around the development of the modified framework for the valuation of ultra-rare diseases.

Ani Khachatourian, PharmD

Strategic Business Consultant
Highmark BCBS

Ani Khachatourian, PharmD, serves as the strategic business consultant, specialty pharmacy at Highmark BCBS, where she leads and participates in various interdisciplinary teams, focused on providing holistic solutions that ensure safe, appropriate, and cost-effective use of specialty drugs at every stage of the patient's journey. She also provides guidance and collaborative oversight of medical policy for Highmark Health, led by evidence-based methodologies and accepted medical practice standards.

PARTICIPANTS

Robert Kinyua, PharmD

Senior Director, Clinical Formulary Development
Prime Therapeutics

Robert Kinyua, PharmD, is a senior director on the formulary development team at Prime Therapeutics. He is responsible for the clinical evaluation models utilized in formulary management for both commercial and Medicare lines of business. Additionally, Robert is responsible for interfacing with, and supporting the Prime National P&T Committee as well as several Blue Cross health plan P&T Committees. His other responsibilities include precepting the Prime resident and pharmacy students as well as lecturing at the University of Minnesota.

Laura Lasiter, PhD

Sr. Director, Policy and Research
PhRMA

Laura Lasiter serves as the senior director, policy and research at PhRMA, where she drives the development of policy positions and research agendas to sustain and improve the policy and regulatory environment for cell and gene therapies, treatments for rare diseases, and biologic medicines. Prior to joining PhRMA in 2021, she served as the director of health policy at the Friends of Cancer Research and ASM/AAAS Congressional Science Fellow. She holds a PhD in biomedical sciences from the University of Tennessee Health Science Center.

Matt Lau, PharmD, MSc

Director, Value Access Insights & Solutions
Takeda

Matt Lau, PharmD, is the director of value access insights & solutions in U.S. medical affairs at Takeda. He is responsible for aligning and developing U.S. medical payer engagement strategy, as well as generation of a scientific platform and associated materials to enable high quality interactions and partnerships with payers and health systems across the portfolio of GI, rare immunology, and plasma-derived therapy medicines.

PARTICIPANTS

Kimberly Lenz, PharmD, FAMCP

Director of Clinical and Operational Pharmacy
MassHealth, Office of Clinical Affairs, Commonwealth Medicine

As Director of Clinical and Operational Pharmacy at the University of Massachusetts Medical School's Commonwealth Medicine Division, Kim Lenz serves MassHealth, the Massachusetts Medicaid Program, and is responsible for the development and oversight of clinical and operational initiatives, with the goal of producing outcomes that deliver appropriate care while managing rising pharmacy costs. Dr. Lenz is an assistant professor in the Department of Family Medicine and Community Health at the University of Massachusetts Medical School.

Nanxin (Nick) Li, PhD, MBA

Senior Director, Market Access Lead
uniQure

Nanxin (Nick) Li, PhD, MBA is currently the senior director, market access lead at uniQure, a leading gene therapy company, where he leads the efforts to demonstrate the value of pipeline products and enable optimal patient access to these therapies. Nick is an experienced leader in integrating value and access into development and commercialization process, optimizing product value proposition throughout life cycle, and delivering reimbursement successes for innovative products. He has a solid track record of making impacts on business.

Robert Lipsy, PharmD. BCPS, BCACP, FASHP

Senior Clinical Pharmacist
MedWiseRx formerly SinfoniaRx

Robert Lipsy, PharmD, BCACP, FASHP, FAzPA is the senior clinical pharmacist for MedWiseRx and associate professor at the College of Pharmacy, University of Arizona. Dr. Lipsy has more than 40 years of experience in academics, hospital, managed care, and medication therapy management. He is a fellow of the American Society of Health-System Pharmacists and in 2001, was awarded the Elias Schlossberg Lifetime Achievement Award by the Arizona Society of Health-System Pharmacists. Dr. Lipsy is also a fellow of AzPA and a member of the association's Hall of Fame.

PARTICIPANTS

Kim McCleary

Founder & CEO
Kith Collective

Kim McCleary has been at the forefront of patient engagement for 30 years. She served as CEO of a national patient advocacy organization for 22 years, followed by six years leading the Patients Count program at FasterCures. In 2018 she founded the Kith Collective to help patient organizations and life science companies better integrate patient perspectives into research and medical product development. Her passion for this work is rooted in lived experience as a patient and a family caregiver.

Tracy McDowd, PharmD, FAMCP

Manager, Clinical Pharmacy
BlueCross BlueShield of Tennessee

Tracy McDowd, PharmD, FAMCP is clinical pharmacy manager, clinical strategy at BlueCross Blue Shield of Tennessee, focusing on Medicare Advantage. Tracy received her doctor of pharmacy degree from University of Tennessee College of Pharmacy and completed a PGY1 Managed Care Pharmacy Residency with Hospital Corporation of America. Her experience includes formulary and utilization management, clinical programs, regulatory compliance, and employer-based MTM programs.

Jamie Miller, RPh

System Director, Managed Care
Pharmacy Services
Geisinger Health Plan

Jamie Miller, RPh, System Director, Managed Care Pharmacy Services brings more than 20 years of experience as a pharmacist and health system leader. In her current role, Ms. Miller oversees the clinical and operational services at Geisinger Health Plan. Geisinger Health Plan serves approximately 540,000 members throughout central and northeastern Pennsylvania and offers commercial, marketplace, Medicare, Medicaid, CHIP, and employer group plans.

PARTICIPANTS

Matt Mitchell, PharmD, MBA

Executive Director, Pharmacy
SelectHealth

Matthew P. Mitchell, PharmD, MBA, FAMCP, is the executive director of pharmacy services for SelectHealth, in Salt Lake City, Utah. Dr. Mitchell has more than 20 years of experience in pharmacy including retail, hospital, and managed care. At SelectHealth, Dr. Mitchell oversees clinical programs, savings initiatives, pharmaceutical rebates, and the specialty and infusible drug network contracting in the management of well over $1 billion claims annually. He chairs the pharmacy and therapeutics committee, as well as several other high-level management strategy and operational committees.



Lilian Ndehi, PharmD, MBA, BCPS

Associate Vice President, Pharmacy Clinical and Specialty Strategies
Humana Inc.

Lilian Ndehi, PharmD, MBA, BCPS, is the associate vice president of pharmacy clinical and specialty strategies at Humana Inc., where she oversees formulary strategy and operations, drug pipeline monitoring and forecasting, policy creation and management, and clinical trend initiatives. She also leads the drug infusion and site of care strategies and the pharmacy managed care residency program. Before taking her current role, Lilian was the patient safety and pharmacy Stars leader where she directed patient safety programs and strategies that promoted clinical quality and health outcomes.

Peter Neumann, ScD

Director
CEVR, Tufts Medical Center

Peter J. Neumann, ScD, is the director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and professor of medicine at Tufts University School of Medicine. He is the founder and director of the Cost-Effectiveness Registry, a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision-making and on regulatory and reimbursement issues in health care.

PARTICIPANTS

Chris Park

Principal Analyst and Data Analytics Advisor
MACPAC

Chris Park is the data analytics advisor and a principal analyst at MACPAC. He focuses on issues related to Medicaid drug policy and managed care payment. He leads MACPAC's data analyses using administrative data and leads the production of the MACStats data book. Prior to joining MACPAC, he was a senior consultant at The Lewin Group. Mr. Park holds a master of science in health policy and management from the Harvard School of Public Health and a bachelor of science in chemistry from the University of Virginia.

Alex Peaslee, PharmD

Senior Drug Information Pharmacist
Navitus Health Solutions

Alex Peaslee is a 2014 graduate of the University of Wisconsin School of Pharmacy and completed a PGY1 Managed Care Residency at Navitus Health Solutions, where he remains employed as a senior drug information pharmacist. His primary responsibilities include oversight of Navitus' National Pharmacy and Therapeutics Committee and formulary drug reviews, as well as monitoring drug development and regulatory approval of novel therapeutics. Alex is also involved in precepting PGY1 residents, interns, and pharmacy students, and has served on AMCP's Format Executive Committee since 2018.

Arlene Price, PharmD

Scientific Director, Value & Evidence Scientific Exchange
Janssen Scientific Affairs

Arlene Price, PharmD, is a clinical pharmacist with thirty years of experience in retail, hospital, academia, managed care, and the pharmaceutical industry. She joined Janssen in 2005, and currently serves as the scientific director for national accounts and provides clinical and health economic support across Janssen's portfolio of products. Previously, Arlene served as the national director of drug policy and clinical outcomes for Prudential Healthcare. She was secretary of the National P&T committee and provided oversight on drug technology coverage decisions for Commercial/Medicare/Medicaid lives.

PARTICIPANTS

Kristen Santiago, MS

Senior Director of Public Policy Initiatives
LUNGevity Foundation

As senior director of public policy initiatives for LUNGevity Foundation, Kristen is focused on breaking down barriers to patient access to high-quality care and treatment innovation. Kristen's previous positions include senior director, policy & advocacy for the Cancer Support Community; director, strategic initiatives & outreach for C-Change; and positions with TAP and Takeda Pharmaceuticals, The Commonwealth of Pennsylvania, and the American Speech-Language-Hearing Association. Kristen earned a master of science in health promotion management at American University and a bachelor of arts in speech language pathology from The George Washington University and is driven by a strong personal desire to impact the health status and quality of life of individuals through strategic alliance development and advocacy.

Michael Sherman, MD, MBA, MS

Executive VP & Chief Medical Officer
Point32Health

Dr. Michael Sherman is the executive vice president and chief medical officer of Point32Health, providing clinical medical leadership to enhance quality of care and outcomes for health care consumers. He is responsible for clinical innovation, quality and accreditation, medical policy, and the Harvard Pilgrim Health Care Institute, which includes the Department of Population Medicine at Harvard Medical School.

Pam Traxel

Senior Vice President
ACS CAN

Pam Traxel serves as the senior vice president for ACS CAN, the advocacy affiliate of the America Cancer Society. Pam is responsible for helping ACS CAN develop relationships with companies and individuals to help further the fight against cancer through dynamic partnerships, events, and forums. She began her career with ACS CAN in 2007 and has been integrally involved in helping to establish ACS CAN as a nationwide advocacy organization that influences and shapes public policy at all levels of government to impact our mission and to represent the voices of all cancer patients and their families.

PARTICIPANTS

Sean Tunis, MD, MSc

Principal
Rubix Health

Sean Tunis, MD, MSc, is a principal with Rubix Health where he consults with public and private sector organizations on health technology issues at the interface of regulatory and reimbursement policy, market access, comparative effectiveness, outcomes measurement, and health technology assessment. He is also a senior fellow in the Tufts Center for the Evaluation of Value and Risk in Health. Dr. Tunis also serves as a Mentor-in-Residence at Johns Hopkins Tech Ventures, helping early-stage companies to develop their initial reimbursement strategy.

John Watkins, PharmD, MPH, BCPS

Residency Program Director
Premera Blue Cross

John is currently the director of Premera's PGY1 Managed Care Pharmacy Residency program and Student Advanced Pharmacy Practice Experience Coordinator. Along with these responsibilities, he manages the pharmacy and therapeutics committee. John is an affiliate professor of pharmacy at the University of Washington. He is board certified in pharmacotherapy and has a PharmD from the University of Washington. He is a member of the ISPOR North American HTA Roundtable and the HTA Council Working Group - Challenges in the Use of HTA in Pluralistic Healthcare Systems. He is a member of the Blue Cross Blue Shield Medical Advisory Panel and ICER member advisory board.

David Whitrap

VP, Communications and Outreach
Institute for Clinical and Economic Review (ICER)

David Whitrap oversees ICER's stakeholder outreach and media relations, highlighting opportunities for organizations throughout the U.S. health system to deliver broad patient access to sustainable, high-value care. Prior to joining ICER, David spent two decades supporting the strategic communications of U.S. government agencies, health care corporations, and other nonprofits. He led external communications for both a large biotech company and a Fortune 20 PBM, and these cross-industry experiences provide him with an unusually broad view of the tensions related to drug innovation, pricing, and access.

PARTICIPANTS

Susan Winckler, RPh, Esq

Chief Executive Officer
Reagan-Udall Foundation for the FDA

Susan C. Winckler, RPh, Esq., is the CEO of the Reagan-Udall Foundation for the Food and Drug Administration. Previously, Winckler served as the president of Leavitt Partners Solutions, a health care strategy firm where she directly advised C-suite executives on public policy/regulation, business strategy, investments, and other matters. A pharmacist and attorney by training, she also served as the CEO of the Food & Drug Law Institute. As Chief of Staff for the FDA (2007-2009), Winckler managed the Commissioner's Office, served both Republican and Democratic commissioners as their senior-most staff adviser.

Gergana Zlateva, PhD

Vice President and Business Lead, Oncology, Patient & Health Impact
Pfizer

Gergana Zlateva is the vice president and business lead for the oncology, patient and health impact group at Pfizer, Inc. Gergana's team provides support in the development and implementation of market access, pricing, reimbursement, and health technology assessment strategies for Pfizer's oncology portfolio. During her 18-year tenure with Pfizer, Gergana has held various positions of increasing responsibility covering health economics, outcomes research, and pricing and reimbursement activities across multiple therapy areas and different geographies. Prior to joining Pfizer, Gergana worked for five years with the United Nations. Gergana holds a PhD in economics from Fordham University and a BA and MPA from Southern Illinois University.

THANK YOU / AMCP STAFF & CONSULTANTS

Susan A. Cantrell, RPh, CAE
Chief Executive Officer

Phil Bongiorno
Vice President, Policy & Government Relations

Liz Colangelo
Senior Manager, Business Strategies

Jim Cooney
Director of Integrated Marketing & Communications

Vyishali Dharbhamalla, PharmD
Senior Manager, Professional Affairs

Paula J. Eichenbrenner, MBA, CAE
Executive Director, AMCP Foundation

Jennifer Evans, PharmD, BCACP, C-TTS
Assistant Director, Educational Programs – Grants

Jennifer Graff, PharmD
Senior Director, Professional Affairs

Julian Greer, CMP, PMP
Senior Manager, Meetings & Forums

Matt Lowe, MSHCA
Vice President, Strategic Alliances & Corporate Services

Noreen Matthews
Senior Consultant

Cindy Reilly, MS, BS Pharm
Chief Operating Officer

Drake Reiter, PharmD, RPh
Executive Fellow in Healthcare Association Leadership

Ruby Singh, PharmD, BCPS
Vice President, Education & Training

Thank You

To our distinguished participants and guests.

•

About AMCP

AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP's diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management, and help patients access cost-effective and safe medications and other therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.

•

AMCP Mission

To improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.

AMCP

Optimizing medicine.
Improving lives.

AMCP | Academy of Managed Care Pharmacy

675 N Washington Street | Suite 220
Alexandria, VA 22314

703 684 2600 | www.amcp.org | @amcporg

Findings and recommendations from this event will be published in an upcoming issue of AMCP's *Journal of Managed Care + Specialty Pharmacy* and will be widely disseminated to decision makers around the country.